Back to mobile site
Get it on Google Play

BioMarin shares five-year Pompe disease drug data at muscle congress

October 2, 2026 11:00 AM EDT Send to a Friend
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) presented five-year Phase 3 open-label extension data for its two-drug combination Pombiliti (cipaglucosidase alfa-atga) and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login